Cap analogs with 5'-terminal acyclic guanosine derivative
AssigneeCureVac AG
InventorsRainer Joachim SCHWARZ, Sarah MORENO
Life of this patent
Estimating the term…
Loading patent…
AssigneeCureVac AG
InventorsRainer Joachim SCHWARZ, Sarah MORENO
Estimating the term…
The present invention is inter alia concerned with (A) a compound of formula (I) as defined herein or a salt, stereoisomer, tautomer or deuterated version thereof, (B) a cap analog comprising a 5′ terminal acyclonucleoside, wherein the acyclonucleoside comprises a linear unbranched or linear single-branched structure of formula (II) instead of a ribose, wherein the 5′ terminal acyclonucleoside is optionally deuterated (C) an RNA molecule comprising at least three nucleotides and comprising a 5′ end of formula (III) as defined herein, wherein the 5′ end is optionally deuterated (D) an RNA molecule comprising at least three nucleotides and comprising a 5′ terminal acyclonucleoside, wherein the acyclonucleoside comprises a linear unbranched or linear single-branched structure of formula (II) instead of a ribose, wherein the 5′ terminal acyclonucleoside is optionally deuterated (E) an in vitro method for synthesizing an RNA molecule, (F) the RNA molecule obtained thereby, (G) compositions comprising the RNA molecule, (H) kits comprising the compound of formula (I) or the cap analog, (J) uses as well as (K) a process for preparing and (L) methods as outlined herein.
A compound of formula (I):
The compound according to any one of the preceding claims, wherein each of n1 and n9 is independently selected from 1 or 2, preferably wherein n1 and n9 are 1.
The compound according to any one of the preceding claims, wherein each of n3, n4, and, if present, each of n6 and n7 is independently selected from 0, 1, or 2, preferably from 0 or 1.
The compound according to any one of the preceding claims, wherein each of R1, R2, R5, R6, R7, R8, Ra, Rb, Rc, Rd, R11, and R12, if present, is the same in each repeating unit.
The compound according to any one of the preceding claims, wherein, if present, one of R1 and R2, one of R5 and R6, one of R7 and R8, one of Ra and Rb, one of Rc and Rd, and one of R11 and R12 is H.
The compound according to any one of the preceding claims, wherein each of R1, R2, R5, R6, R7, R8, Ra, Rb, Rc, Rd, R11, and R12, if present, is H.
The compound according to any one of the preceding claims, wherein
The compound according to any one of the preceding claims, wherein
The compound according to any one of the preceding claims, wherein
The compound according to any one of the preceding claims, wherein
The compound according to any one of the preceding claims, wherein L1 is selected from the group consisting of CH2, O, S, SO, SO2, NH, CH(OH), CH(SH) and CH(halogen), with the proviso that, if m is 1 and n2, n5 and n8 are O, L1 is selected from the group consisting of O, S, SO, SO2 and NH.
The compound according to any one of the preceding claims, wherein L1 is selected from the group consisting of CH2, O, CH(OH), CH(SH) and CH(halogen), preferably consisting of CH2 and O, with the proviso that, if m is 1 and n2, n5 and n8 are O, L1 is O or S, preferably O.
The compound according to any one of the preceding claims, wherein L2, if present, is O.
The compound according to any one of the preceding claims, wherein
The compound according to any one of the preceding claims, wherein B2 is selected from the group consisting of guanine, a modified guanine, a guanine analog, adenine, a modified adenine, and an adenine analog.
The compound according to any one of the preceding claims, wherein B3 is guanine, a modified guanine or a guanine analog.
The compound according to any one of the preceding claims, wherein ring B1 is a modified guanine, preferably selected from the group consisting of N7-methylguanine, N7-4-chloro-benzyl-guanine, N7-biphenyl-methylene-guanine, N7-naphtyl-methylene-guanine and N7-3,5-dimethyl-benzyl-guanine.
The compound according to any one of the preceding claims, wherein ring B1 is N7-methylguanine.
The compound according to any one of the preceding claims, wherein n10 is 1.
The compound according to any one of the preceding claims, wherein X1 is CH2 or O, and each of X2 through X8 is O.
The compound according to any one of the preceding claims, wherein each of Y1 through Y5 is O;
The compound according to any one of the preceding claims, wherein each of Z1 through Z5 is OH.
A cap analog comprising a 5′ terminal acyclonucleoside, wherein the acyclonucleoside comprises a linear unbranched or linear single-branched structure instead of a ribose, wherein the cap analog is preferably a Cap1 analog or a Cap2 analog or a Cap2-1 analog, wherein the 5′ terminal acyclonucleoside is optionally deuterated, and wherein the linear unbranched or linear single-branched structure has the structure of formula (II):
An RNA molecule comprising at least three nucleotides and comprising a 5′ end of formula (III)
An RNA molecule comprising at least three nucleotides and comprising a 5′ terminal acyclonucleoside, wherein the acyclonucleoside comprises a linear unbranched or linear single-branched structure instead of a ribose, wherein the 5′ terminal acyclonucleoside is optionally deuterated, and wherein the linear unbranched or linear single-branched structure has the structure of formula (II):
A process for preparing a compound of formula (I):
Dependencies are inferred from the claim text.